Independent panel finds alteplase beneficial for acute stroke patientsBMJ 2003; 326 doi: https://doi.org/10.1136/bmj.326.7401.1234 (Published 05 June 2003) Cite this as: BMJ 2003;326:1234
- Jeanne Lenzer
A review of an earlier study of the use of alteplase has confirmed that the drug, when given according to the study's protocol, reduced disability in patients with acute stroke.
The review was undertaken after a controversy sparked off by an article in the BMJ last year (2002;324: 723-9). The earlier study was published in the New England Journal of Medicine more than seven years ago (1995;333: 1581-7).
The BMJ article said that the original study was cited as the reason why the American Heart Association had changed its guidelines on the use of alteplase but pointed out that most of the association's experts on stroke had ties to the drug's manufacturer. The article provoked numerous letters, many of which pointed to possible weaknesses in the original study.
The new review was carried out by an independent panel set up by the National Institute of Neurological Diseases and Stroke (NINDS), which conducted the trial. The results of the review were announced at the annual meeting of the Society of Academic Emergency Medicine in Boston last week.
The panel, chaired by W Michael O'Fallon, a professor of biostatistics, said that analyses confirmed the trial's finding that alteplase, delivered according to its protocol, reduced disability in patients with acute stroke. …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial